Market capitalization | $12.79m |
Enterprise Value | $17.81m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-20.48m |
Cash position | $1.90m |
EPS (TTM) EPS | $-2.15 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
2 Analysts have issued a NRX Pharmaceuticals Inc forecast:
2 Analysts have issued a NRX Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
0%
0%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -20 -20 |
38%
38%
|
Net Profit | -20 -20 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Head office | United States |
CEO | Jonathan Javitt |
Founded | 2017 |
Website | www.nrxpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.